Evidence map›Paper›PMID 36523391›Full record

ArticleClinical case reports2022

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.

Margaux Lelong, Jean-Luc Raoul, Yann Touchefeu, Jean-Marie Berthelot, Paul Arnolfo, Tamara Matysiak-Budnik, Hélène Senellart

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Metastatic pancreatic acinar cell carcinoma withJournal of gastrointestinal oncology · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Margaux LelongDepartment of Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France.
Jean-Luc RaoulDepartment of Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France.ORCID https://orcid.org/0000-0001-6305-8953
Yann TouchefeuDepartment of Gastroenterology, (IMAD) University Hospital Nantes France.
Jean-Marie BerthelotDepartment of Rhumatology University Hospital Nantes France.
Paul ArnolfoDepartment of Rhumatology University Hospital Nantes France.
Tamara Matysiak-BudnikDepartment of Gastroenterology, (IMAD) University Hospital Nantes France.ORCID https://orcid.org/0000-0003-0780-6261
Hélène SenellartDepartment of Medical Oncology Institut de Cancérologie de l'Ouest Saint-Herblain France.
Centre Hospitalier Universitaire de Nantes · FRInstitut de Cancérologie de l'Ouest · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This 38-year-old man has a familial BRCA2 mutation. He presented with skin erythema, polyarthritis, dactylitis, and febrile erythema nodosum; a biopsy of a liver metastase revealed acinar cell carcinoma of the pancreas. After FOLFIRINOX, olaparib was initiated, and 24 months after, the patient was PS 0 and asymptomatic.

Indexed as

BRCA mutationlipaselong survivalpancreatic acinar cell cancerpanniculitis

Identifiers

PMID36523391
PMCPMC9744715
OpenAlexW4311213555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.